These disorders involve the dysfunctional metabolism of sphingolipids, which are fats found in cell membranes (so it is a kind of sphingolipidosis, which is included in the larger family of lysosomal storage diseases).
- 1 Signs and symptoms
- 2 Causes
- 3 Pathophysiology
- 4 Diagnosis
- 5 Treatment
- 6 Prognosis
- 7 Incidence
- 8 History
- 9 Research
- 10 See also
- 11 References
- 12 External links
Signs and symptoms
Symptoms are related to the organs in which sphingomyelin accumulates. Enlargement of the liver and spleen (hepatosplenomegaly) may cause reduced appetite, abdominal distension, and pain. Enlargement of the spleen (splenomegaly) may also cause low levels of platelets in the blood (thrombocytopenia).
Accumulation of sphingomyelin in the central nervous system (including the cerebellum) results in unsteady gait (ataxia), slurring of speech (dysarthria), and difficulty swallowing (dysphagia). Basal ganglia dysfunction causes abnormal posturing of the limbs, trunk, and face (dystonia). Upper brainstem disease results in impaired voluntary rapid eye movements (supranuclear gaze palsy). More widespread disease involving the cerebral cortex and subcortical structures causes gradual loss of intellectual abilities, causing dementia and seizures.
Bones also may be affected, with the disease causing enlarged bone marrow cavities, thinned cortical bone, or a distortion of the hip bone called coxa vara. Sleep-related disorders also occur with the condition, such as sleep inversion, sleepiness during the day and wakefulness at night. Gelastic cataplexy, the sudden loss of muscle tone when the affected patient laughs, is also seen.
Mutations in the SMPD1 gene cause Niemann–Pick disease types A and B. They produce a deficiency in the activity of the lysosomal enzyme acid sphingomyelinase, that breaks down the lipid sphingomyelin.
Type D originally was separated from type C to delineate a group of patients with otherwise identical disorders who shared a common Nova Scotian ancestry. Patients in this group are known to share a specific mutation in the NPC1 gene, so NPC is used for both groups. Before the molecular defects were described, the terms "Niemann–Pick type I" and "Niemann–Pick type II" were proposed to separate the high- and low-sphingomyelin forms of the disease in the early 1980s.
Niemann–Pick disease is inherited in an autosomal recessive pattern, which means both copies, or both alleles of the gene, must be defective to cause the disease. "Defective" means they are altered in a way that impairs their function. Most often, the parents of a child with an autosomal recessive disorder are carriers: they have one copy of the altered gene, but are not affected because the other copy produces the enzyme. If both parents are carriers, each pregnancy has a 25% chance of producing an affected child. Genetic counseling and genetic testing are recommended for families who may be carriers of the disease.
Niemann–Pick diseases are a subgroup of lipid storage disorders called sphingolipidoses in which harmful quantities of fatty substances, or lipids, accumulate in the spleen, liver, lungs, bone marrow, and brain.
In the classic infantile type-A variant, a missense mutation causes complete deficiency of sphingomyelinase. Sphingomyelin is a component of cell membrane including the organellar membrane, so the enzyme deficiency blocks degradation of lipid, resulting in the accumulation of sphingomyelin within lysosomes in the macrophage-monocyte phagocyte lineage. Affected cells become enlarged, sometimes up to 90 μm in diameter, secondary to the distention of lysosomes with sphingomyelin and cholesterol. Histology shows lipid-laden macrophages in the marrow and "sea-blue histiocytes" on pathology. Numerous small vacuoles of relatively uniform size are created, giving the cytoplasm a foamy appearance.
For type A and B, levels of sphingomylinase can be measured from a blood sample. To diagnose type C, a skin sample can help determine whether the transporter is affected.
There are four types of Niemann–Pick disease in two categories. Patients with ASM deficiency are classified into type A and B. Type A patients exhibit hepatosplenomegaly in infancy and profound central nervous system involvement and unable to survive beyond two years of age. Type B patients also show hepatosplenomegaly and pathologic alterations of their lungs but usually without the involvement of their central nervous system. Some can develop significant life-threatening complications including liver failure, hemorrhage, oxygen dependency, pulmonary infections, and splenic rupture. Some develop coronary artery or valvular heart disease. In a longitudinal natural history study, nearly 20% of the patients died. For those classified into type C, they may have mild hepatosplenomegaly, but their central nervous system is profoundly affected.
- Niemann–Pick disease, SMPD1-associated, which includes types A and B
- Niemann–Pick disease type A: classic infantile
- Niemann–Pick disease type B: visceral
- Niemann–Pick disease, type C: subacute/juvenile, includes types C1 (95% of type C) and C2. Type C is the most common form of the disease Type C2 is a rare form of the disease.
Niemann–Pick disease type D (or Nova Scotia form) is now believed to be the same condition as Niemann–Pick disease type C. Two poorly characterized forms of Niemann–Pick disease have also been described as types E and F.
No specific treatment is known for type A, but symptoms are treated.
In adult patients with type B, physicians try to keep cholesterol levels down to normal levels. If statins are used, they monitor liver function. If the spleen is enlarged and platelet levels low, acute episodes of bleeding may require transfusions of blood products. If they have symptoms of interstitial lung disease, they may need oxygen.
Anecdotally, organ transplant has been attempted with limited success. Future prospects include enzyme replacement and gene therapy. Bone marrow transplant has been tried for type B.
In January 2009, Actelion announced the drug miglustat (Zavesca) had been approved in the European Union for the treatment of progressive neurological manifestations in adult patients and pediatric patients with NPC. The drug is available to patients in the United States on an experimental basis. In March 2010, the FDA requested additional preclinical and clinical information regarding Zavesca from Actelion before making a final decision on approving the drug in the United States for NPC.
Type A Niemann–Pick disease (about 85% of cases) has an extremely poor prognosis, with most cases being fatal by the age of 18 months. Type B (adult onset) and type C (mutation affecting a different molecule) Niemann–Pick diseases have a better prognosis.
The incidence among Ashkenazi Jews is estimated to be about one in 40,000 for type A of Niemann–Pick disease. The incidence of both Niemann–Pick disease types A and B in all other populations is estimated to be one in 250,000. The incidence of Niemann–Pick disease type C is estimated to be one in 150,000.
Albert Niemann published the first description of what now is known as Niemann–Pick disease, type A, in 1914. Ludwig Pick described the pathology of the disease in a series of papers in the 1930s.
In 1961, the classification of Niemann–Pick disease into types A, B, and C was introduced, and also contained a type D, called the "Nova Scotian type". Genetic studies showed that type D is caused by the same gene as type C1, and the type D designation is no longer used.
Research has been ongoing to better understand the disease and treatments for it.
The loss of myelin in the central nervous system is considered to be a main pathogenic factor. Research uses animal models carrying the underlying mutation for Niemann–Pick disease, e.g. a mutation in the NPC1 gene as seen in Niemann-Pick type C disease. In this model, the expression of myelin gene regulatory factor (MRF) has been shown to be significantly decreased. MRF is a transcription factor of critical importance in the development and maintenance of myelin sheaths. A perturbation of oligodendrocyte maturation and the myelination process might, therefore, be an underlying mechanism of the neurological deficits.
Curiously, in 2011 fibroblast cells derived from patients with Niemann-Pick type C1 disease were shown to be resistant to Ebola virus because of mutations in the NPC1 protein, which is needed for viral escape from the vesicular compartment.
Other studies have unturned small molecules which inhibit the receptor and may be a potential therapeutic strategy.
Treatments under investigation
Experimental use of arimoclomol
In 2014 the European Medicines Agency (EMA) granted orphan drug designation to arimoclomol for the treatment of Niemann-Pick type C. This was followed in 2015 by the U.S. Food & Drug Administration (FDA). Dosing in a placebo-controlled phase II/III clinical trial to investigate treatment for Niemann-Pick type C (for patients with both type C1 and C2) using arimoclomol began in 2016.
Experimental use of 2-hydroxypropyl-β-cyclodextrin
Researchers at the University of Arizona first proposed the use of 2-hydroxypropyl-β-cyclodextrins (HPBCD)for the treatment of Niemann Pick Type C1 in 2001. Researchers noted that HPBCDs, with varying levels of 2-hydroxypropyl substitution, had effects in delaying neurological symptoms and in decreasing liver cholesterol storage in a Niemann Pick mouse model. Later, researchers at the University of Texas Southwestern Medical Center found that when Niemann–Pick type C mice were injected with 2-hydroxypropyl-β-cyclodextrin (HPbCD) when they were 7 days old, they showed marked improvement in liver function, much less neurodegeneration and ultimately, they lived longer lives than the mice who did not receive this treatment. These results suggest HPbCD acutely reverses the storage defect seen in NPC.
In April 2011, the U.S. National Institutes of Health (NIH), in collaboration with the Therapeutics for Rare and Neglected Diseases Program (TRND), announced they are developing a clinical trial using HPbCD for Niemann–Pick type C patients. The clinical trial is in the planning phase, not yet approved by the FDA.
- "Niemann–Pick". Oxford English Dictionary (3rd ed.). Oxford University Press. September 2005. (Subscription or UK public library membership required.)
- James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. p. 536. ISBN 978-0-7216-2921-6.
- "Neimann-Pick Disease". Genetics Home Reference. NIH. January 2008. Retrieved 2 October 2012.
- Schuchman, Edward H.; Wasserstein, Melissa P. (2015). "Types a and B Niemann-Pick disease". Best Practice & Research Clinical Endocrinology & Metabolism. 29 (2): 237–247. doi:10.1016/j.beem.2014.10.002. PMID 25987176.
- Sphingomyelinase Deficiency at eMedicine
- "Niemann Pick Disease Type C". National Organization for Rare Disorders.
- "NIEMANN-PICK DISEASE, TYPE B". OMIM. 9 April 2019. 607616.
- Sphingomyelinase Deficiency~treatment at eMedicine
- "Actelion Pharmaceuticals Ltd (CH) - Actelion receives FDA complete response letter for Zavesca (miglustat) for the treatment of Niemann-Pick type C disease" (Press Release). Drugs.com. 9 March 2010.
- Dermatologic Manifestations of Niemann-Pick Disease at eMedicine
- niemann at NINDS
- synd/1029 at Who Named It?
- Niemann, A. (1914). "Ein unbekanntes Krankheitsbild" [An unknown disease picture]. Jahrbuch für Kinderheilkunde. Neue Folge (in German). 79: 1–10.
- Pick, L. (1926). "Der Morbus Gaucher und die ihm ähnlichen Krankheiten (die lipoidzellige Splenohepatomegalie Typus Niemann und die diabetische Lipoidzellenhypoplasie der Milz)" [Gaucher's disease and similar diseases (type Niemann lipoid cell splenohepatomegaly and spleen diabetic lipoid cell hypoplasia)]. Ergebnisse der Inneren Medizin und Kinderheilkunde (in German). 29: 519–627.
- Crocker, Allen C. (1961). "The Cerebral Defect in Tay-Sachs Disease and Niemann-Pick Disease". Journal of Neurochemistry. 7: 69–80. doi:10.1111/j.1471-4159.1961.tb13499.x. PMID 13696518.
- Online Mendelian Inheritance in Man (OMIM) Niemann–Pick Disease, Type C1; NPC1 -257220
- Yan, Xin; Lukas, Jan; Witt, Martin; Wree, Andreas; Hübner, Rayk; Frech, Moritz; Köhling, Rüdiger; Rolfs, Arndt; Luo, Jiankai (2011). "Decreased expression of myelin gene regulatory factor in Niemann-Pick type C 1 mouse". Metabolic Brain Disease. 26 (4): 299–306. doi:10.1007/s11011-011-9263-9. PMID 21938520.
- Koenning, M.; Jackson, S.; Hay, C. M.; Faux, C.; Kilpatrick, T. J.; Willingham, M.; Emery, B. (2012). "Myelin Gene Regulatory Factor is Required for Maintenance of Myelin and Mature Oligodendrocyte Identity in the Adult CNS". Journal of Neuroscience. 32 (36): 12528–12542. doi:10.1523/JNEUROSCI.1069-12.2012. PMC 3752083. PMID 22956843.
- Carette, Jan E.; Raaben, Matthijs; Wong, Anthony C.; Herbert, Andrew S.; Obernosterer, Gregor; Mulherkar, Nirupama; Kuehne, Ana I.; Kranzusch, Philip J.; Griffin, April M.; Ruthel, Gordon; Cin, Paola Dal; Dye, John M.; Whelan, Sean P.; Chandran, Kartik; Brummelkamp, Thijn R. (2011). "Ebola virus entry requires the cholesterol transporter Niemann–Pick C1". Nature. 477 (7364): 340–343. Bibcode:2011Natur.477..340C. doi:10.1038/nature10348. PMC 3175325. PMID 21866103.
- Côté, Marceline; Misasi, John; Ren, Tao; Bruchez, Anna; Lee, Kyungae; Filone, Claire Marie; Hensley, Lisa; Li, Qi; Ory, Daniel; Chandran, Kartik; Cunningham, James (2011). "Small molecule inhibitors reveal Niemann–Pick C1 is essential for Ebola virus infection". Nature. 477 (7364): 344–348. Bibcode:2011Natur.477..344C. doi:10.1038/nature10380. PMC 3230319. PMID 21866101.
- "European Medicines Agency - - EU/3/14/1376". www.ema.europa.eu. 2018-09-17.
- "Search Orphan Drug Designations and Approvals". www.accessdata.fda.gov.
- "Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C - Full Text View - ClinicalTrials.gov". clinicaltrials.gov.
- Camargo, Fernando; Erickson, Robert P.; Garver, William S.; Hossain, G.Showkat; Carbone, Peter N.; Heidenreich, Randall A.; Blanchard, James (2001). "Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease". Life Sciences. 70 (2): 131–142. doi:10.1016/S0024-3205(01)01384-4.
- Liu, B.; Turley, S. D.; Burns, D. K.; Miller, A. M.; Repa, J. J.; Dietschy, J. M. (2009). "Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/- mouse". Proceedings of the National Academy of Sciences. 106 (7): 2377–2382. doi:10.1073/pnas.0810895106. PMC 2650164. PMID 19171898.
- "Therapeutics for Rare and Neglected Diseases Program". U.S. National Institutes of Health. November 2017.
- Hempel, Chris (13 April 2011). "FDA Filing Made Requesting Use of Medtronic SynchroMed Pump To Deliver Cyclodextrin To Brain". Addi and Cassi blog. Retrieved 22 June 2013.
|Wikimedia Commons has media related to Niemann–Pick disease.|